A high prevalence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) has been observed among the Asian population, along with significantly lower survival rates reported in previous real-world studies compared to clinical trials. Here, EGFR is linked to non-small cell lung carcinoma.